Rihas Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 31-10-2024
- Paid Up Capital ₹ 0.10 M
as on 31-10-2024
- Company Age 3 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2023)
- Net Worth -50.00%
(FY 2023)
- Total Assets 5.00%
(FY 2023)
About Rihas Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Srinisha Jagathrakshakan and Narayanasamy Elamaran serve as directors at the Company.
- CIN/LLPIN
U24230TN2021PTC146359
- Company No.
146359
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Sep 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rihas Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Srinisha Jagathrakshakan  | Director | 21-Sep-2021 | Current |
| Narayanasamy Elamaran | Director | 21-Sep-2021 | Current |
Financial Performance and Corporate Structure Insights of Rihas Pharma.
Rihas Pharma Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 50%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Rihas Pharma?
Unlock access to Rihas Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Sam Tools Private LimitedActive 41 years 6 monthsSrinisha Jagathrakshakan and Narayanasamy Elamaran are mutual person
Panyam Cements And Mineral Industrties LimitedActive 69 years 6 monthsSrinisha Jagathrakshakan and Narayanasamy Elamaran are mutual person
Fortune Distillers And Vintners Private LimitedActive 15 years 4 monthsSrinisha Jagathrakshakan is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Rihas Pharma?
Rihas Pharma has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rihas Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rihas Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
